RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Clinical trials for RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug trial offers hope for Tough-to-Treat amyloidosis

Disease control Recruiting now

This study is testing an experimental drug called linvoseltamab in people with AL amyloidosis that has returned or hasn't responded to prior treatments. The first phase will find the safest dose, and the second phase will see how well it works to reduce the harmful proteins and i…

Matched conditions: RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Get alerted when new RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS trials appear

New drug trial offers hope for Tough-to-Treat amyloidosis